The Recall Desk
SevereFDA (Drugs)·D-0178-2025·Announced 2025-01-15

Clonazepam tablets recalled for incorrect carton labeling

Endo USA is recalling approximately 9,816 cartons of Clonazepam 2 mg tablets due to incorrect strength labeling on the carton exterior. The blister strips inside contain the correct formulation.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: FDA Class I classification mandates minimum severity of Severe. Although the actual product inside contains the correct formulation, incorrect labeling on a controlled substance creates potential for medication errors.

Plain-English summary

Clonazepam 2 mg orally disintegrating tablets (60 tablets per carton) manufactured by Endo USA and distributed by PAR Pharmaceutical have been recalled due to labeling errors. Approximately 9,816 cartons with lot numbers 550176501 and 550176601 (expiring 02/28/2027) were distributed nationwide.

Some cartons contain incorrect labeling on the declared strength. However, the blister strips (the actual tablets) inside each affected carton contain the correct strength formulation.

Patients nationwide who received medications from the affected lots should check their carton labeling against their prescription to ensure accuracy. If the carton labeling does not match the prescribed strength, patients should contact their pharmacy or healthcare provider before taking the medication.

The recalled product

Product
CLONAZEPAM (CLONAZEPAM)
Brand
CLONAZEPAM
Manufacturer
Endo USA, Inc.
Hazard
  • mis-labeling
  • strength-error

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (3)

  • Lot # 550176501
  • 550176601
  • Exp 02/28/2027.

Distribution

Distributed nationwide across the United States.